Ningbo Menovo Pharmaceutical Second Quarter 2024 Earnings: EPS: CN¥0.022 (vs CN¥0.054 loss in 2Q 2023)

Simply Wall St · 09/01 01:01

Ningbo Menovo Pharmaceutical (SHSE:603538) Second Quarter 2024 Results

Key Financial Results

  • Revenue: CN¥345.1m (up 2.7% from 2Q 2023).
  • Net income: CN¥4.90m (up from CN¥12.6m loss in 2Q 2023).
  • Profit margin: 1.4% (up from net loss in 2Q 2023).
  • EPS: CN¥0.022 (up from CN¥0.054 loss in 2Q 2023).
earnings-and-revenue-growth
SHSE:603538 Earnings and Revenue Growth September 1st 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

Ningbo Menovo Pharmaceutical Earnings Insights

Looking ahead, revenue is forecast to grow 32% p.a. on average during the next 2 years, compared to a 12% growth forecast for the Pharmaceuticals industry in China.

Performance of the Chinese Pharmaceuticals industry.

The company's shares are up 5.0% from a week ago.

Risk Analysis

Before you take the next step you should know about the 1 warning sign for Ningbo Menovo Pharmaceutical that we have uncovered.